Jul 31st 2012 - Edison Investment Research today published a report on BB Biotech entitled "Discount Management Tops Agenda". In summary, the report says:
BB Biotech (BION) invests globally in companies active in the biotechnology sector. Biotech has been one of the best-performing elements within healthcare in recent months, supported by fundamental drivers and M&A interest from big pharma companies seeking to replenish their product pipelines. Within this, individual stock performance reflects the binary nature of biotech investing, and individual investors may benefit from the diversification offered by a collective fund managed by a sector specialist. The proposed tax-efficient distribution policy implies a yield of c 5%, with continuing share buybacks.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »